Strategy Dashboard · Compiled May 6, 2026
Portrait of Elizabeth Dreicer

Elizabeth Dreicer

Podcast Strategy

Your Biology and Future(working title)

Conversations about your biology, your data, and what you own.

The rules for what you can do with your own biology, what other people can do with it, and what happens when something goes wrong are still being written. Whoever writes them owns the next 25 years of medicine.
Anchor: MyBioBank consumer launch · September 2026
Elizabeth's concept

What this show is, why it matters

In the next 25 years, more is going to change about your body, your biology, your health, your data, and what you own than has changed in the last century. The show is about who is writing the rules, who is fighting for them, and who they are protecting.

Elizabeth's unique intersection

The seat only Elizabeth fills

A 25-year health philanthropist simultaneously running a clinical-trial economic-flip company (Consuli, contracting with named pharma sponsors), a chartered AI-and-health-data rules consortium (ATIA), and a consumer biobank product (MyBioBank), all backed by named foundations with bipartisan policy traction in Congress. Operator credibility, philanthropic capital fluency, AI-infrastructure governance, bipartisan policy traction, and consumer-facing institutional product all in one person. The combination does not exist anywhere else in this conversation.

Elizabeth's niche

Three content pillars, one through-line

1
Policy & Governance
Policymakers, foundations
2
AI & Health Data Infrastructure
AI builders, policy-curious foundations
3
Personal Biology
Longevity-curious consumers, ramping toward MyBioBank launch
Operating principles

The five-principle lens behind every strategy

This strategy is designed to show you how our process works — how we think about media and how we get you in front of the people who matter most to your organization. These five core principles are the lens through which we build every strategy, so you can see exactly how we’ll make you successful.

Each lane has a real pain in their own voice, a reachable subset in year one, and a pre-warmed pool the show can convert.

Policy

The Bipartisan Staffer

I'm writing policy on biology I don't fully understand
Primary pain. Writing the next bill on biology you do not fully understand yet

TAM

100,000+
  • Federal Hill staff (~18,500)
  • state legislators (~7,383)
  • state AGs (50)

SOM (year one)

2,500
~2,000 senior staffers across Senate Judiciary, Senate HELP, House Energy & Commerce, House Judiciary, House AI Task Force orbit, plus 50 state AGs and 200-300 active state legislators on health and tech committees

Reachable share of addressable population

SOM 2,5002.5% of TAM
There is no data privacy law that protects genomic data, no provision in the bankruptcy code that prevents this data from being compromised through a bankruptcy auction.Sen. Chuck Grassley

Guest targets

Senate Judiciary genetic data hearing witnessesCornyn / Grassley / Klobuchar Senate officesLofgren / Cline House officesHouse AI Task Force staff (Obernolte / Lieu)
AI Builders

The Specialty AI Founder

I have the model. I can't get the data.
Primary pain. We hit a data wall. We can't train without high-quality experimental data, and we can't get high-quality experimental data without legitimate consented pathways at scale.

TAM

15,000+
  • Approximately 1,500 active digital health companies (Galen Growth) at 5-10 senior decision-makers per company. Specialty subset: 188-326 health-AI startups specifically.

SOM (year one)

3,000
~300 specialty health-AI startups with priority subset of 100 vertical players at Series A-C. At 5-10 senior decision-makers per company: 1,500-3,000 reachable in year one.

Reachable share of addressable population

SOM 3,00020.0% of TAM
Predictive models can't be trained without high-quality experimental data.Molly Gibson, Lila Biosciences

Guest targets

Vertical AI founders in oncology, cardiometabolic, mental-health, diabetes, clinical-research AISeries A-C founders facing the data wallAI-and-data-licensing legal scholars
Foundations

The Foundation Steward

We have the capital. We need the thesis.
Primary pain. We have endowment dollars and no credible health-data infrastructure to deploy into. We can write grants all day. What we cannot do is deploy our endowment into infrastructure vehicles that have credible governance, mission alignment, and competitive returns.

TAM

145,000+
  • US private foundations filing IRS Form 990-PF (~145,000)
  • active in health (~1,500-2,000)
  • GIIN-tracked impact-investing organizations globally (3,907)

SOM (year one)

1,500
~150 US-based health-focused foundations with $200M+ in assets and active impact-investing posture, at 5-10 senior decision-makers per foundation

Reachable share of addressable population

SOM 1,5001.0% of TAM
Foundation impact investments help bring capital to communities that have been overlooked, [to] address the root causes of health inequities.Robert Wood Johnson Foundation

Guest targets

RWJF program-related-investments leadSkoll Foundation principalsPrebys FoundationLeonard Family Foundation
Consumers

The Longevity-Curious Consumer

I want to control my biology before someone else does
Primary pain. I gave my biology to a company once and they sold it through bankruptcy. I do not want to do that again, but I also do not want to be the person whose grandchild needed a cell I should have stored.

TAM

129,000,000+
  • 50% of US adults extremely or very concerned about DNA-testing data sharing (Pew). 74% want stricter genetic data regulation (~191M). 87% want it illegal for insurers/employers to access DTC genetic info (~225M).

SOM (year one)

1,900,000
1.9 million 23andMe deletion-requesters since March 2025 bankruptcy (uniquely qualified pre-warming pool). Plus 5-10M broader longevity-curious organic reach window leading into September 2026 launch.

Reachable share of addressable population

SOM 1,900,0001.5% of TAM
Should I delete my 23andMe data?most-trafficked consumer search post-bankruptcy

Guest targets

23andMe deletion-requester narrativesLong-COVID patient who participated in early Consuli sessionsParent who banked stem cells before chemotherapyPatient advocate who turned diagnosis into a research foundation
The five operating principles

The five-principle lens behind every strategy

Five proven levers, distilled from 180M+ downloads and 200+ founders. Together they are the system that allows a business to win. Click any card to expand the principle in detail.

Industry Thought Leader is the practice of producing media that positions you and your organization as the leading voice in your category. There is an art to this. It works by speaking directly to every flavor of motivation an audience brings, so the people you most want to reach actually see themselves in the work and convert into your universe.

The way we do it is simple: tailor every piece of content to a specific audience problem. We interweave case studies, human stories, and concrete value across all four lanes so each motivation type has something to grab onto. We call this hacking the back of the brainstem— speaking to the real challenge sitting in the audience’s head before anything else.

Below: the four lane-specific challenges this show is built to answer, plus the cross-lane challenge underneath them all, each paired with the content solution we’d build for it.

1Policy challenge:Writing the next bill on biology you do not fully understand yet
Content solution
Before You Write the Next One: What Every Health Policy Staffer Needs to Know About 2026 Biology

A senior staffer is being asked to mark up a genetic privacy bill, an AI-in-healthcare provision, or a child-data-protection clause without a clean mental model of what induced pluripotent stem cells, autologous CAR-T, AI-mediated diagnostics, and biobank custody actually do. Elizabeth opens with a structured ground-truth briefing on the science and governance gaps a bill needs to anticipate.

2AI Builders challenge:I have the model. I cannot get the data.
Content solution
The Data Wall: Why Your Health AI Is Sitting on Shaky Legal Ground, and What Comes Next

A specialty AI founder building an oncology, cardiometabolic, or behavioral-health AI has the modeling talent, the team, and a paying pilot. What they do not have is consented patient data at the scale and provenance their next legal review will demand. Elizabeth walks through what failed in the consumer-data-cooperative wave (LunaDNA, Nebula Genomics, Embleema, Hu-manity), what Datavant and Komodo Health solve for pharma, and what ATIA is built to provide for AI builders specifically.

3Foundations challenge:We have the capital. We need the thesis.
Content solution
Endowment Dollars in Health Data Infrastructure: The Thesis Foundation Boards Will Actually Defend

A program officer or CIO at a $200M to $2B health-focused foundation has watched RWJF commit $625M and Skoll Foundation deploy 80% of endowment in social impact. They want to do something similar but cannot find a credible health-data-infrastructure vehicle that survives the toughest skeptic on their board. Elizabeth hosts that skeptic out loud: a peer foundation principal walking through how they sized the thesis.

4Consumers challenge:I deleted my 23andMe data. What now?
Content solution
After 23andMe: How to Think About Your Biology When You Cannot Trust the Custodian

1.9 million people requested that 23andMe delete their genetic data after the bankruptcy filing. Many discovered that requesting deletion and verifying deletion are not the same thing. The show talks directly to the consumer who lived this and is now ready to think about biological data sovereignty as an asset, not just a worry.

5All four lanes challenge:We have the substance. We do not have the centerpiece.
Content solution
Why the Most Important Conversations in Health Are Happening in Rooms Most People Are Not In

A foundation, an academic center, a patient advocacy organization, or an AI builder is doing important work, sending it to congressional staffers, and watching it land in a few inboxes. Elizabeth makes the structural argument for why category-defining work needs a centerpiece conversation, not just a library.

The Mini Celebrity Effect is the idea that you only need to be known by your ideal audience. We focus on the 1,000 true fans principle — one thousand of the right people seeing you as the go-to person in your field.

The way to do this is to create perception. When the audience sees the content, the show, and the brand, they should be looking at someone with high status, authority, deep knowledge, lived experience, and a serious network around them. The people we want to reach need to walk away with the right impression of the problems we are solving and the company we are solving them with.

The effect is built by combining two things: your subject-matter expertise and the quality of your network. Together they position the founder and the organization as the trusted, sought-after figure inside the niche. Below: the four lane-specific strategies that put those two elements to work.

1Policy strategy:Put the Bipartisan Coalition in the Guest Chair
Strategy detail
What
Bring on the principals and senior staff behind the Don't Sell My DNA bipartisan coalition (Cornyn, Grassley, Klobuchar in Senate; Lofgren, Cline in House) one office at a time.
Why
Each episode gives staffers an unfiltered briefing from the people writing the bill, and signals to every other policy office in the orbit that Elizabeth is the operator they should be calling when the next genetic-privacy or health-AI bill moves.
2AI Builders strategy:Stage the ATIA Working Sessions
Strategy detail
What
Bring on the first wave of specialty AI founders willing to test or adopt the ATIA framework: oncology AI, diabetes AI, cardiometabolic AI, mental-health AI. Each episode is part pitch, part working session, part public commitment.
Why
By the time ATIA launches publicly, Elizabeth has a roster of named participants the show recruited on air. The episodes also become the canonical explainer assets ATIA needs anyway.
3Foundations strategy:Run the Foundation Principals Series
Strategy detail
What
Host RWJF, Skoll, Prebys, Leonard Family Foundation, McKnight, and a dozen other foundation impact-investing leads modeling their thesis publicly to peers.
Why
Every guest is a foundation that has now publicly committed to a posture, and every other foundation watching is now considering the same posture. The most direct lever the show pulls on the remaining $300M+ of the $600M endowment fundraise.
4Consumers strategy:Bring the Human Stories of Personal Biology Into the Centerpiece Conversation
Strategy detail
What
Re-mobilize five years of Consuli relationships and the Trust's National Health Council and Health Record Banking Alliance partnerships to feature real human stories: the 23andMe customer who tried to delete their data, the long-COVID patient, the parent who banked stem cells before chemotherapy, the patient advocate who turned diagnosis into infrastructure.
Why
Other shows in the lane cover policy and infrastructure as policy and infrastructure. None of them tell the human story underneath. That seat is Elizabeth's. The consumer audience the show needs to warm by September 2026 remembers the person, not the bill number.

What this compounds into

Operator-of-record status on biodata sovereignty and health-AI governanceA recruitment pipeline into ATIAA recruitment pipeline into the remaining endowment fundraiseBipartisan policy traction that compoundsA consumer audience pre-warmed for September 2026A library that finally has a centerpiece

The Lead Flow Tap is the system that turns the show into a continuous, predictable inflow of the right people. Every episode is a public-facing artifact, but underneath it sits a LinkedIn outreach engine reaching 1,000 targeted prospects per month across the four lanes the trust actually needs to convert.

The way we think about this is simple: every individual the show is built to reach is a target. Not an abstract audience segment — a specific person, in a specific seat, with a specific reason to lean in. The four targets below are the four kinds of people the show converts: the staffer writing the bill, the founder hitting the data wall, the foundation principal sizing the thesis, the consumer who already lost their data once.

For each target we name why they convert and what the show compounds into — the strategic value the trust actually gets when this person enters the universe. Underneath that, we map the market opportunity — where this audience lives, how big it is, and the funnel that turns reach into qualified conversations every month.

1Target 1 · Policy:Senior Congressional Staff and Committee Leads on Health, Judiciary, AI, and Energy & Commerce
Target detail
Why
First audience the show reaches because it is the audience the trust is already partly reaching badly. Senior staff actively writing genetic-privacy and health-AI legislation.
Path
Episode-by-episode, this audience converts from 'people Elizabeth emails' into 'people whose offices invite Elizabeth to brief.' Compounds into bipartisan policy traction the trust uses for every subsequent legislative cycle.
2Target 2 · AI Builders:Specialty Health-AI Founders, CTOs, and Heads of Data at Series A-C Vertical AI Startups
Target detail
Why
300+ tracked health-AI startups in 2026 with $4B in AI-enabled US digital health raised in H1 2025. Operator layer at the specialty / vertical end (oncology, cardiometabolic, mental health, diabetes, clinical-research AI).
Path
Each guest converts from a recruitment target into an ATIA participant, and the canonical episodes become the assets ATIA uses to onboard the rest of the ecosystem.
3Target 3 · Foundations:Foundation Principals, Endowment CIOs, and PRI Leads at Health-Focused Foundations
Target detail
Why
US foundations sit on roughly $1.75T in assets. RWJF deployed $325M new in 2024 (total $625M). Skoll has 80% of endowment in social impact. The next layer of foundations watching this work is large and capital-rich.
Path
Every guest is a prospective co-investor in the remaining $300M+ of the trust's $600M endowment fundraise. The episodes become the deck the next foundation principal brings to their own investment committee.
4Target 4 · Consumers:Longevity-Curious Consumers (Pre-Warmed Through Months 4-6 Toward September 2026 MyBioBank Launch)
Target detail
Why
The 23andMe bankruptcy created a uniquely qualified consumer cohort (1.9M deletion-requesters, ~15% of 15M-customer base). The longevity-tech category (Altos Labs, NewLimit, Retro Biosciences, Lifeforce, Function Health) made stem-cell banking and cellular reprogramming part of mainstream consumer vocabulary.
Path
The show is the warm-pool builder for the trust's first consumer product.

Your Biology and Future is built around four named audiences. We size the total audience the show can plausibly reach, narrow it to the serviceable obtainable market we actually convert, show where that audience already lives, and then walk the monthly funnel that turns reach into compounding conversations.

Total addressable audience

The specific people the show is built to reach. Each circle is a counted audience. Consumers form the outer universe; the three B2B audiences sit inside it, scaled in proportion to each other.
129MConsumers23andMe-affected pool145KFOUNDATIONS100KPOLICY15KAI BUILDERSB2B audiences sized in proportion to each other · Consumer universe is roughly 1,000x larger

Serviceable obtainable market

Out of the total, the named decision-makers and pre-warmed cohorts the show can actually convert.
Consumers (pre-warmed)1,900,000
AI Builders3,000
Policy2,500
Foundations1,500
B2B headline. 5,000-8,000 senior B2B decision-makers.  Consumer headline. 5-12M reachable consumers leading into September 2026.

Where this audience lives

LinkedIn is where the four lanes converge. It is also where the platform itself is moving the audience the show needs.

Senior congressional staffers, health-AI founders, and foundation program officers all maintain active LinkedIn presences. It is the primary content and social-connection platform for the B2B layer of the show, and it is where authority transfer is most visible: titles, employer history, and endorsements are public, so credibility moves with the post.

The platform is also accelerating in exactly the formats the show is built to win on. Video viewership on LinkedIn grew +36% year-over-year in early 2025, and video creation is growing at twice the rate of other post formats (Digiday, 2025). Cross-platform benchmarks show video impressions up 73% and video views up 52% from 2024 to 2025 (Teleprompter / Metricool 2026), while post comments rose 24% YoY in the most recent quarter (Social Media Today, Oct 2025). The 2025 Edelman + LinkedIn B2B Thought Leadership Report makes the strategic case explicit: thought leadership content opens doors with senior buyers that ads and traditional sales cannot (Edelman + LinkedIn, 2025).

Translation for the show: founders and operators who put long-form video and consistent content on LinkedIn right now are getting disproportionately in front of the exact decision-makers the trust needs — staffers, AI founders, foundation principals — and the platform’s own algorithm is amplifying that work.

65M+
Senior decision-makers on LinkedIn globally (LinkedIn data)
10M+
C-level executives reachable on the platform (LinkedIn data)
+36%
YoY growth in LinkedIn video viewership, early 2025 (Digiday)
2x
Video creation growth vs. other post formats (LinkedIn / Digiday)
101K+
Active US health-policy LinkedIn job listings (the trust’s adjacent talent pool)
6
Named podcast peers already in this audience’s listening set

Growth funnel

A custom LinkedIn outreach system that compounds attention into qualified conversations every month.

From 1,000 targeted touchpoints to 5–15 qualified conversations / month

Each gate is conservative; the system runs continuously across the four core audience lanes.
Top of funnel
1,000 / mo
Targeted outreaches
Custom LinkedIn outreach system reaching qualified individuals across Policy, AI Builders, Foundations, and Consumers.
20–30%
Engagement
Engaged audience
200–300 / mo
New connections & engaged individuals
This is how we grow the audience — people now in your orbit, seeing your content, recognizing the brand.
10–20%
Qualified
Qualified individuals
20–60 / mo
Direct, subject-matter conversations
Engaging directly on what you do, how you help people in the world, and the relationship between them and your business.
10–25%
Converted
Opportunities
5–15 / mo
Booked calls, partners, prospects
Compounding monthly — the conversations that turn into ATIA partners, endowment relationships, and MyBioBank traction.
What we mean by “qualified”
Someone directly talking to you about what you do and how you help people in the world — engaging in your subject matter and in the relationship between them and your organization. Not a vanity metric. A real conversation.
What are 5–15 new qualified conversations worth to your business every month?
Arguably one of the most valuable things this system does — and the reason the rest of the principles compound.

The Mirror Effectis how you become omnipresent in the mind of your ideal buyer or audience member. What we’re after is strategic omnipresence — a deliberate act of staying top of mind across platforms, formats, and channels.

The way to think about it is as a touchpoint journey: every individual moves from awareness to conversion through repeated, consistent contact with your work. The biggest brands and creator-founders all understand this, and so does every paid-ad strategy ever built. The math is simple — the more often the right person sees the right content, the more likely they convert.

To create that journey, we build the Mirror Flywheel: record long-form episodes, slice them into dozens of high-impact assets, distribute them across every relevant platform, and recirculate the wins. One long-form piece becomes dozens of touchpoints. The effect builds mental stickiness, increases conversion rates, and compresses the time from discovery to decision.

STEP 1
Record
Long-form episodes with depth and authority
STEP 2
Slice
Viral trailers, social media shorts, quote graphics, blog posts, email sequences
STEP 3
Distribute
LinkedIn, YouTube Shorts, Instagram, Email, Blog, Podcast Platforms
STEP 4
Recirculate
Highlight wins, re-share frameworks, and loop old content into new offers

Each long-form episode feeds 8-20+ touchpoints across LinkedIn, YouTube, Instagram, email, and the blog. The flywheel runs continuously, not in campaigns.

One of Oneis how you become the only choice in everyone’s mind. This is the final principle — what everything else in the strategy layers up to. This is category ownership: when your brand, your voice, and your frameworks show up consistently, people stop comparing you to anyone else and start associating you as the only person who actually solves their problem.

Our system builds that message into your podcast, your content, your LinkedIn, your videos, your features, and the rest of your ecosystem. The objective is that when anyone in your audience thinks or searches the questions below, they don’t deliberate, they don’t go hunting for alternatives. They think of you, and they call you.

There is no federal data privacy law that protects genomic data, no provision in the bankruptcy code that prevents this from happening again, and I am the staffer being asked to draft a response. Who can actually explain the biology to me before I mark up this bill?
My specialty AI model is one legal review away from being indefensible because of how we sourced training data. Where is the rules-of-the-road framework I can adopt before that review happens?
My investment committee is going to ask me, again, why we are deploying endowment dollars into health-data infrastructure instead of sticking to grants. I need a thesis another foundation has already defended in front of its board.
I deleted my 23andMe data after the bankruptcy. I do not believe it actually got deleted. Where do I store my biology in a way I can actually trust for the next thirty years?
What does the future look like when we have all stored our younger selves and we are using our own biology to keep ourselves from getting cancer?
When policymakers, AI builders, and the people whose biology is at stake think about who governs personal sovereignty over health data, they don't Google. They don't compare. They call the Global BioData Trust.
Competitive landscape

Where Elizabeth sits that no one else does

Positioning white space
The operator-philanthropist's seat in the conversation about who governs personal biology in the AI era. No competitor occupies it. Elizabeth uniquely qualifies.

Grouped by what each one is. Direct attempts that did not work, indirect B2B players, and aspirational benchmarks the show treats as guests.

Direct attempts (closed, pivoted, faded)

LunaDNA (LunaPBC)
Member-owned data-sharing platform for health research
Couldn't bridge B2C→B2B economics at scale; structural argument for the trust model (Closed January 31, 2024)
Nebula Genomics
Tokenized genomic ownership (George Church)
Token-incentive model couldn't sustain governance integrity (Pivoted to 'DNA Complete' sequencing lab in 2024)
Embleema
Originally Ethereum patient data; now multimodal RWE for pharma
Consumer-control branding survives only as long as B2B revenue allows (Pivoted from consumer ownership to pharma B2B)
Hu-manity.co
Personal data as property rights via blockchain app
Property-rights framing survives even where the company didn't (Faded post-2020)

Indirect B2B players

Datavant
Privacy-preserving data linkage tokenization · Pharma, life sciences, providers, payers
Provider/pharma-mediated layer (different from ATIA's patient/AI-mediated layer)
Komodo Health
Real-Time Healthcare Data Map covering 330M+ US patients · Life sciences research
Provider/pharma-mediated layer
Truveta
14+ health systems data co-op covering >15% of US patient care · Life sciences researchers
Provider-led data co-op (vs. patient-led trust)

Aspirational benchmarks

RWJF / Skoll Foundation
Foundation impact-investing benchmarks
Guest priorities, not competitors

Peers graded by audience and format proximity. The operator-philanthropist seat — the one Your Biology and Future is built for — is empty across this entire set.

Closest peerSame audience & format / fundingAdjacentReal overlap, different seatAdjacent (lighter)Overlap exists, depth differsMore removedInsider lane audience touches
ShowHost · NetworkCadenceLanePeer fitGap vs Your Biology and Future
TradeoffsAppleSitePenn LDIDan GorensteinIndependent (RWJF / CHCF / Penn LDI funded)BiweeklyHealth policy journalismClosest peerClosest production and funding peer in the set. NYT Daily-style narrative format directly maps to where this show could go; foundation-funding model maps to how it could be sponsored. Lane gap is journalism vs operator — Gorenstein analyzes; Elizabeth builds. Rarely covers biodata sovereignty, biology + AI infrastructure, or consumer biobanking.
Ground TruthsAppleSpotifySubstackYouTubeEric Topol, MDSubstack / Scripps ResearchWeeklyAI in medicine (academic-clinical)AdjacentStrongest known voice on AI in medicine. High-credibility academic-clinical lens; Topol speaks doctor-to-doctor. Real audience overlap with this show’s clinician and AI-builder lanes, but Topol is positioned as a clinician analyzing the field, while Elizabeth is positioned as an operator building inside it. No policy lens, no consumer surface, no operator-as-builder seat.
Medicine and the MachineAppleSpotifyMedscapeEric Topol + Abraham VergheseMedscapeWeeklyClinician-humanism on AI in medicineAdjacent (lighter)Same lane as Ground Truths but more clinician-humanism balance via Verghese’s storytelling sensibility. Even more clinician-centric than Ground Truths and locked to Medscape’s editorial frame. Same gaps as Ground Truths: no policy, no consumer, no operator.
Raising Health (formerly Bio Eats World)a16zAppleOlivia Webb / Kris TatiossianAndreessen Horowitz (a16z) Bio + Health~WeeklyVC + biotech operatorAdjacentVC frame everywhere. Strong founder access; speaks operator-to-operator on the AI-and-biology side. Real audience overlap with the specialty health-AI builder lane, but Elizabeth occupies a different seat (operator-philanthropist vs VC-operator) with different capital fluency (philanthropic + endowment vs venture). No policy lens, no consumer biology surface, no philanthropic / impact-investing frame.
The Long RunAppleSpotifySiteLuke TimmermanTimmerman ReportSemimonthlyBiotech / pharma insiderMore removedPharma-insider lane with CEO-grade guest pipeline (Moderna, BridgeBio, Xaira, Penn CAR-T, Blueprint). Insider-to-insider conversations. Audience touches policymakers and AI builders but lives a step removed from the seats this show targets. Useful as a guest-relationship reference, not a competitive peer.
POLITICO Pulse CheckAppleChelsea CirruzzoPOLITICOWeeklyHealth policy news (reporter-driven)Adjacent (lighter)Tight news cycle, real staffer reach via POLITICO’s distribution. Reporter-driven journalism rather than operator-led depth. News-driven and ephemeral; no through-line, no narrative arc, no operator perspective, low biology depth. Useful as a topical-cycle reference, not a competitive peer for the operator-philanthropist seat.
Your Biology and FutureElizabeth DreicerThe Global BioData TrustWeeklyOperator-philanthropistThe empty seatLong-form video interviews. Operator credibility, philanthropic capital fluency, AI-infrastructure governance, bipartisan policy traction, and consumer-facing institutional product — in one seat. No one currently sits here.
Proof

Founders we've done this for

10 years. 180M+ downloads. 200+ founders behind these covers.

Click any cover to read their story
Execution timeline

Three phases into September 2026

The phase structure is in place. Specifics — lane focus, primary strategy per phase, and recruitment outcome — are to be discussed and locked on our next step call.

Phase 1
June-July 2026
Months 1-2
Policy lane
Bipartisan staffer rotation
Build the Hill-briefing reputation
Phase 2
August-September 2026
Months 3-4
Foundation Principals series + ATIA Working Sessions in parallel
Endowment recruitment + AI-builder recruitment
Convert guests into ATIA participants and endowment co-investors
Phase 3
September 2026 onward
Months 5+
Consumer human-stories activation
MyBioBank launch flagship cadence; B2B lanes continue
Convert pre-warmed audience into MyBioBank early adopters
Recruitment thesis. Every episode targets two pipelines simultaneously: ATIA participants (specialty AI builders) and endowment co-investors (foundation principals). A small number of qualified conversations close enormous amounts of strategic value.
To be discussed
Three phases. Details locked on the next step call.
We’ll align on the lane focus, primary strategy, and the recruitment outcome for each phase together — then this section fills in.
Next step call · pending